• 1
    Collinge J., Sidle K.C., Meads J., Ironside J., Hill A.F. (1996) Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383: 68590.
  • 2
    Luhr K.M., Nordstrom E.K., Low P., Ljunggren H.G., Taraboulos A., Kristensson K. (2004) Scrapie protein degradation by cysteine proteases in CD11c+ dendritic cells and GT1-1 neuronal cells. J Virol 78: 477682.
  • 3
    Sassa Y., Inoshima Y., Ishiguro N. (2009) Bovine macrophage degradation of scrapie and BSE PrPSc. Vet Immunol Immunopathol 133: 339.
  • 4
    Luhr K.M., Wallin R.P., Ljunggren H.G., Low P., Taraboulos A. & Kristensson K. (2002). Processing and degradation of exogenous prion protein by CD11c+ myeloid dendritic cells in vitro. J Virol 76: 12,25964.
  • 5
    Ma J.Y., Lindquist S. (2001) Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci USA 98: 14,95560.
  • 6
    Shinagawa M., Munekata E., Doi S., Takahashi K., Goto H., Sato G. (1986) Immunoreactibity of a synthetic pentadecapeptide corresponding to the N-terminal region of the scrapie prion protein. J Gen Virol 67: 174550.
  • 7
    Clarke MC and Haig DA (1970). Evidence for the multiplication of scrapie agent in cell culture. Nature 225: 100101.
  • 8
    Yedidia Y., Horonchik L., Tzaban S., Yanai A., Taraboulos A. (2001) Proteasomes and ubiquitin are involved in turnover of the wild-type prion protein. EMBO J 20: 538391.
  • 9
    Doh-ura K., Iwaki T., Caughey B. (2000) Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 74: 48947.
  • 10
    Kim C.L., Karino A., Ishiguro N., Shinagawa M., Sato M., Horiuchi M. (2004) Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J Gen Virol 85: 347382.
  • 11
    Wadsworth J.D., Joiner S., Hill A.F., Campbell T.A., Desbruslais M., Luthert P.J., Collinge J. (2001) Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 358: 17180.
  • 12
    Kim C.L., Umetani A., Matsui T., Ishiguro N., Shinagawa M., Horiuchi M. (2004) Antigenic characterization of an abnormal isoform of prion protein using a new disease panel of monoclonal antibodies. Virology 320: 4051.
  • 13
    Rybner-Barnier C., Jacquemot C., Cuche C., Dore G., Majlessi L., Gabellec M., Moris A., Schwarts O., Santo J., Cumano A., Leclerc C., Lazarini F. (2006) Processing of the bovine spongiform encephalopathy-specific prion protein by dendritic cells. J Virol 80: 465663.
  • 14
    Nakamitsu S., Kurokawa A., Yamasaki T., Uryu M., Hasebe R. Horiuchi M. (2009) Cell density-dependent increase in the level of protease-resistant PrP in prion-infected neuro2a mouse neuroblastoma cells. J Gen Virol 91: 1539.
  • 15
    Rabinowitz S., Horstmann H., Gordon S., Griffiths G. (1992) Immunocytochemical characterization of the endocytic and phagolysosomal compartments in peritoneal macrophages. J Cell Biol 116: 95112.
  • 16
    Verhoef L.G., Lindsten K., Masucci M.G., Dantuma N.P. (2002) Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet 11: 2689700.
  • 17
    Beauvillain C., Delneste Y., Scotet M., Peres A., Gascan H., Guermonprez P., Barnaba V., Jeannin P. (2007) Neutrophils efficiently cross-prime naive T cells in vivo. Blood 110: 296573.
  • 18
    Heiseke A., Aguib Y., Schaetzl H.M. (2009) Autophagy, prion infection and their mutual interactions. Curr Issues Mol Biol 12: 8798.